MINSTRY-SCINCE-ICT-FUTUR
31 promising Korean startups are attending TNW Conference Europe 2017 (hereafter “the Conference”) to be held May 18-19, 2017, in Amsterdam, Netherlands.
31 Promising startups of Korea will showcase advanced technologies such as Fintech based on blockchain, nano new materials, eco-friendly products, IoT and software service to the European market.
Ministry of Science, ICT and Future Planning (hereafter “MSIP”), Ministry of Culture, Sports & Tourism and Small and Medium Business Administration of the Korean government are making joint efforts in backing tech startups to advance into the European market under the name of K-Startup.
Mr. Koh Kyeongmo, Deputy Minister for Creative Economy Coordination in MSIP showed high expectations for the Conference in that it will trigger promotion of Korean startups’ tech capabilities on the global stage and attract substantial investment in the future.
TNW Conference Europe 2017
This is the largest tech conference in Europe having been initiated from 2006 and it consists of programs including workshops, tailored networking events for startups and exhibitions. It is expected to attract about 20,000 participants and 4,000 companies who are tech investors, accelerators and startups from over 100 countries.
The Korean government will increase the support for Korean tech startups pioneering into the European market by utilizing the venue of the Conference.
Korea in TNW Conference
In the Conference, the Korean government is operating K-Startup Pavilion which displays products and services from various fields such as iris recognition devices and solutions, drones with one-handed controllers, seed packages and portable hydro-power generators.
In particular, the Korean government will cohost Investor Dinner with TNW, thereby fostering networking of global investors. In the venue, around 80 promising investors handpicked by TNW along with some Korean startups participate.
Furthermore, 7 Korean startups are advancing to the semi-final round of competition which guarantees them the chance to pitch in Arena. In the competitions, Korean startups’ innovative products will be promoted and the startups will compete to be award-winners.
31 Promising Startups of Korea
Major Korean startups will take part in the Conference. For example, Smart Study , a kids-content startup having exceeded 15.5m dollars in sales as of 2016 will attend the event. Studio XID , a software startup of which its service is used by global companies such as Google, Facebook, Baidu and Alipay will also participate. For detailed information on best Korean startups, please visit here or watch K-Startup Show reel.
- Smart Study: www.smartstudy.co.kr
- Studio XID: www.protopie.io
- KOREA STARTUPS: http://thewelcome.ipdisk.co.kr/publist/VOL1/guest/Korea%20Startup%20IR%20Report%20Edition.pdf
- K-Startup Show reel: http://thewelcome.ipdisk.co.kr:80/publist/VOL1/guest/K_Startup_TNW%20Showreel.mp4
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005049/en/
Contact:
Ministry of Science, ICT and Future Planning
Yang Yunay, +82 2 2110
2086
Deputy Director
yunay@korea.kr
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom